S&P 500   3,981.00 (-2.64%)
DOW   31,950.59 (-2.16%)
QQQ   297.74 (-2.75%)
AAPL   143.89 (-3.58%)
MSFT   258.51 (-3.11%)
FB   197.87 (-2.34%)
GOOGL   2,272.00 (-2.47%)
AMZN   2,188.91 (-5.13%)
TSLA   741.29 (-2.67%)
NVDA   175.38 (-3.52%)
BABA   89.77 (-2.41%)
NIO   16.41 (-1.32%)
AMD   100.40 (-2.02%)
CGC   5.79 (-1.70%)
MU   72.72 (-2.36%)
T   20.38 (-0.92%)
GE   75.69 (-0.93%)
F   13.00 (-3.92%)
DIS   105.76 (-2.65%)
AMC   13.36 (+3.57%)
PFE   50.85 (-0.95%)
PYPL   78.77 (-1.23%)
NFLX   184.40 (-3.23%)
S&P 500   3,981.00 (-2.64%)
DOW   31,950.59 (-2.16%)
QQQ   297.74 (-2.75%)
AAPL   143.89 (-3.58%)
MSFT   258.51 (-3.11%)
FB   197.87 (-2.34%)
GOOGL   2,272.00 (-2.47%)
AMZN   2,188.91 (-5.13%)
TSLA   741.29 (-2.67%)
NVDA   175.38 (-3.52%)
BABA   89.77 (-2.41%)
NIO   16.41 (-1.32%)
AMD   100.40 (-2.02%)
CGC   5.79 (-1.70%)
MU   72.72 (-2.36%)
T   20.38 (-0.92%)
GE   75.69 (-0.93%)
F   13.00 (-3.92%)
DIS   105.76 (-2.65%)
AMC   13.36 (+3.57%)
PFE   50.85 (-0.95%)
PYPL   78.77 (-1.23%)
NFLX   184.40 (-3.23%)
S&P 500   3,981.00 (-2.64%)
DOW   31,950.59 (-2.16%)
QQQ   297.74 (-2.75%)
AAPL   143.89 (-3.58%)
MSFT   258.51 (-3.11%)
FB   197.87 (-2.34%)
GOOGL   2,272.00 (-2.47%)
AMZN   2,188.91 (-5.13%)
TSLA   741.29 (-2.67%)
NVDA   175.38 (-3.52%)
BABA   89.77 (-2.41%)
NIO   16.41 (-1.32%)
AMD   100.40 (-2.02%)
CGC   5.79 (-1.70%)
MU   72.72 (-2.36%)
T   20.38 (-0.92%)
GE   75.69 (-0.93%)
F   13.00 (-3.92%)
DIS   105.76 (-2.65%)
AMC   13.36 (+3.57%)
PFE   50.85 (-0.95%)
PYPL   78.77 (-1.23%)
NFLX   184.40 (-3.23%)
S&P 500   3,981.00 (-2.64%)
DOW   31,950.59 (-2.16%)
QQQ   297.74 (-2.75%)
AAPL   143.89 (-3.58%)
MSFT   258.51 (-3.11%)
FB   197.87 (-2.34%)
GOOGL   2,272.00 (-2.47%)
AMZN   2,188.91 (-5.13%)
TSLA   741.29 (-2.67%)
NVDA   175.38 (-3.52%)
BABA   89.77 (-2.41%)
NIO   16.41 (-1.32%)
AMD   100.40 (-2.02%)
CGC   5.79 (-1.70%)
MU   72.72 (-2.36%)
T   20.38 (-0.92%)
GE   75.69 (-0.93%)
F   13.00 (-3.92%)
DIS   105.76 (-2.65%)
AMC   13.36 (+3.57%)
PFE   50.85 (-0.95%)
PYPL   78.77 (-1.23%)
NFLX   184.40 (-3.23%)
LON:VAL

ValiRx (VAL) Share Forecast, Price & News

GBX 25.34
-1.91 (-6.99%)
(As of 05/18/2022 02:49 PM ET)
Add
Compare
Today's Range
25.13
▼
26.52
50-Day Range
20.98
▼
34.25
52-Week Range
17.26
▼
65
Volume
67,393 shs
Average Volume
545,530 shs
Market Capitalization
£16.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ValiRx and its competitors with MarketBeat's FREE daily newsletter.

ValiRx logo

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate VAL201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

Headlines

May 17, 2022 | americanbankingnews.com
ValiRx (LON:VAL) Stock Price Crosses Above 50-Day Moving Average of $26.98
May 7, 2022 | americanbankingnews.com
ValiRx (LON:VAL) Stock Price Passes Below 200-Day Moving Average of $30.57
April 29, 2022 | americanbankingnews.com
ValiRx (LON:VAL) Stock Price Crosses Below 200 Day Moving Average of $30.91
March 24, 2022 | lse.co.uk
Valirx News Headlines. VAL Share News. Financial News Articles for Valirx Plc Ord 0.1P updated throughout the day. - London South East
March 23, 2022 | morningstar.co.uk
TRADING UPDATES: Arecor Therapeutics wins patent... - Morningstar
March 23, 2022 | marketwatch.com
ValiRx Says Proposed Sublicense of VAL201 Product Delayed by Global Events - MarketWatch
March 15, 2022 | morningstar.co.uk
TRADING UPDATES: Amigo heads to vote; UniVision court date pushed back - Morningstar
March 15, 2022 | lse.co.uk
AIM WINNERS & LOSERS: Eco Animal expects earnings below consensus | Financial News - London South East
March 15, 2022 | morningstar.co.uk
AIM WINNERS & LOSERS: Eco Animal expects earnings below consensus - Morningstar
March 15, 2022 | marketwatch.com
ValiRx Mulling Options to Create Drug Development Infrastructure; Shares Rise - MarketWatch
February 14, 2022 | morningstar.co.uk
TRADING UPDATES: BioPharma backs Collegium; Eurasia... - Morningstar
February 8, 2022 | proactiveinvestors.com
The Cenkos Securities Growth & Innovation Forum - Proactive Investors USA
January 6, 2022 | morningstar.co.uk
ValiRx enters agreement and potential sub-license with TheoremRx - Morningstar
See More Headlines

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:VAL
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.valirx.com
Phone
+44-20-30084416
Fax
N/A
Employees
10
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
GBX 1.82 per share
Price / Cash Flow
13.96
Book Value
GBX 6.40 per share
Price / Book
3.96

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
1.67
Current Ratio
16.74
Quick Ratio
16.74

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
65,049,000
Free Float
N/A
Market Cap
£16.49 million
Optionable
Not Optionable

Company Calendar

Last Earnings
9/07/2020
Today
5/18/2022

MarketRank™

Overall MarketRank™

0.69 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













ValiRx (LON:VAL) Frequently Asked Questions

How were ValiRx's earnings last quarter?

ValiRx plc (LON:VAL) posted its quarterly earnings data on Monday, September, 7th. The company reported ($4.43) earnings per share for the quarter.
View ValiRx's earnings history.

Who are ValiRx's key executives?
ValiRx's management team includes the following people:
  • Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D., CEO & Director (Age 44, Pay $38.38k)
  • Mr. James Gerry Desler FCA, CFO & Exec. Director (Age 66, Pay $65.04k)
  • Mr. Kevin J. Alexander, Sec. & Independent Non-Exec. Director (Age 66, Pay $65.62k)
  • Mr. Kumar Nawani, Head of Operations
  • Mr. Tarquin Edwards, Head of Investor Relations & Communications
  • Mr. Mark Treharne, Corp. Devel. Mang.
What other stocks do shareholders of ValiRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), boohoo group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR).

What is ValiRx's stock symbol?

ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How do I buy shares of ValiRx?

Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is ValiRx's stock price today?

One share of VAL stock can currently be purchased for approximately GBX 25.34.

How much money does ValiRx make?

ValiRx has a market capitalization of £16.49 million.

How many employees does ValiRx have?

ValiRx employs 10 workers across the globe.

What is ValiRx's official website?

The official website for ValiRx is www.valirx.com.

How can I contact ValiRx?

ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.